Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function

Abstract

Novel compounds for treatment of cancer and disorders associated with angiogenesis function. Also disclosed are a method of preparing the compounds, pharmaceutical compositions and packaged products containing the compounds, a method of using these molecules to treat cancer (e.g., leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, breast cancer, renal cancer, and prostate cancer) and disorders associated with angiogenesis function (e.g., age-related macular degeneration, macular dystrophy, and diabetes), a method of monitoring the treatment, a method of profiling gene expression, and a method of modulating gene expression.

1 - 26 . (canceled) 
     
     
         27 . A method of inducing cytotoxicity in cancer cells, comprising:
 contacting cancer cells selected from the group consisting of leukemia, non-small cell lung cancer, central nervous system (CNS) cancer, ovarian cancer, breast cancer, renal cancer, prostate cancer, colon cancer, and melanoma, with an effective amount of a compound of Formula II,   
       
         
           
           
               
               
           
         
         wherein
 R is H, alkyl, or halogen; 
 R′ is H, alkyl, or halogen; 
 X is CH; and 
 Y comprises a homocyclic or heterocyclic ring. 
 
       
     
     
         28 . The method of  claim 27 , wherein Y is 2-pyrazinyl or 2-, 3-, 4-pyridinyl. 
     
     
         29 . The method of  claim 27 , wherein the compound is selected from the group consisting of 
       
         
           
           
               
               
           
         
       
     
     
         30 . The method of  claim 28 , wherein the compound is selected from the group consisting of 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         31 . A pharmaceutical composition comprising a carrier and an effective amount of a compound of Formula II, 
       
         
           
           
               
               
           
         
         wherein
 R is H, alkyl, or halogen; 
 R′ is H, alkyl, or halogen; 
 X is CH; and 
 Y comprises a homocyclic or heterocyclic ring. 
 
       
     
     
         32 . The pharmaceutical composition of  claim 31 , wherein Y is 2-pyrazinyl or 2-, 3-, 4-pyridinyl. 
     
     
         33 . The pharmaceutical composition of  claim 31 , wherein the compound is selected from the group consisting of 
       
         
           
           
               
               
           
         
       
     
     
         34 . The pharmaceutical composition of  claim 32 , wherein the compound is selected from the group consisting of